An investigation on behalf of investors of Portola Pharmaceuticals Inc (NASDAQ:PTLA) shares over potential securities laws violations in connection certain financial statements was announced.

Investors who purchased shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA), have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 – 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Portola Pharmaceuticals Inc (NASDAQ:PTLA) concerning whether certain statements regarding by Portola Pharmaceuticals’ business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) grew from $20.09 per share in May 2014 to as high as $49.77 per share in September 2015.

On February 26, 2016, Portola Pharmaceuticals Inc reported its fourth quarter and year end 2015 financial results and provided a corporate update. Portola Pharmaceuticals Inc reported that its annual total Revenue rose from $9.62 million in 2014 to $12.07 million in 2015, while its Net Loss increased from $137.12 million in 2014 to $226.50 million in 2015.

On March 24, 2016 Portola Pharmaceuticals Inc announced data from the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study, which evaluated the superiority of extended-duration anticoagulation with oral betrixaban compared with standard of care anticoagulation with injectable enoxaparin for the prevention of venous thromboembolism (VTE), or blood clots, in acute medically ill patients.

Shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) declined to as low as $18.20 per share on March 28, 2016.

On April 1, 2016, NASDAQ:PTLA shares closed at $21.29 per share.

Those who purchased shares of Portola Pharmaceuticals Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
[email protected]

The post Portola Pharmaceuticals Inc (NASDAQ:PTLA) under Investigation for Investors over possible Violations of Securities Laws appeared first on Octafinance.